Preclinical studies demonstrate that IL-1β inhibition synergizes with immune checkpoint inhibitors to enhance anti-tumor efficacy in murine models, likely by reversing TME-mediated immune suppression [206]. This evidence concerns the gene IL1B and neoplasm.